European regulators have cleared Pfizer’s Mylotarg to treat a certain subset of patients with acute myeloid leukaemia (AML). More: Pfizer’s Mylotarg wins EU approval for AML Source: News
read moreBranded drugmakers have balked at the U.S. Patent and Trademark Office’s inter partes review system almost since its inception seven years ago. One reason? “It’s unconstitutional,” the companies contend. On Tuesday, the U.S. Supreme Court disagreed. More: In a blow for pharma, Supreme Court upholds
read moreIt’s been a painful few years for Orexigen Therapeutics in the obesity arena, and the company is finally ready to bow out. The San-Diego based drugmaker has inked a pact with Nalpropion Pharmaceuticals—a new company funded in part by specialty
read moreAstraZeneca has come up short in another lung cancer trial of its immuno-oncology combo, this time in patients who’ve failed on two prior treatments. But investors shouldn’t use the outcome to predict the forthcoming results of a closely watched first-line study,
read moreIt’s been a good news-bad news 24 hours for Eli Lilly. Its closely watched RA prospect baricitinib didn’t exactly sail through Monday’s FDA committee meeting. But Tuesday morning, Lilly rolled out Q1 results that beat sales and earnings expectations. Upshot?
read moreBiogen’s Spinraza sales increased only modestly, but the newly launched rare disease drug has tough numbers to top after last year’s monster rollout, CEO Michael Vounatsos said Tuesday. And a new marketing campaign could help. But what about those MS
read more© 1994 - 2026 B.M. Pharmaceuticals